Correction: Clinical and cost-effectiveness of an intervention for reducing cholesterol and cardiovascular risk for people with severe mental illness in English primary care: a cluster randomised controlled trial (The Lancet Psychiatry (2018) 5(2) (145–154), (S2215036618300075) (10.1016/S2215-0366(18)30007-5));Clinical and cost-effectiveness of an intervention for reducing cholesterol and cardiovascular risk for people with severe mental illness in English primary care: a cluster randomised controlled trial

The Lancet Psychiatry

Volumn 5, Issue 2, 2018, Pages 145-154

  Osborn, David ^a,b   Burton, Alexandra ^a   Hunter, Rachael ^a   Marston, Louise ^a   Atkins, Lou ^a   Barnes, Thomas ^c   Blackburn, Ruth ^a   Craig, Thomas ^d   Gilbert, Hazel ^a   Heinkel, Samira ^a   Holt, Richard ^e   King, Michael ^a,b   Michie, Susan ^a,b   Morris, Richard ^a,f   Morris, Steve ^a,f   Nazareth, Irwin ^a   Omar, Rumana ^a   Petersen, Irene ^a   Peveler, Robert ^e   Pinfold, Vanessa ^g   Walters, Kate ^a   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ST PANCRAS HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f UNIVERSITY OF BRISTOL   (United Kingdom)

^g Faculty of ArtsThe McPin Foundation   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; BEHAVIOR CHANGE; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ENGLAND; FEMALE; GENERAL PRACTICE; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; MALE; MEDICATION COMPLIANCE; MENTAL DISEASE; OBESITY; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PRIMARY MEDICAL CARE; PRIMULA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TOTAL CHOLESTEROL LEVEL; WAIST CIRCUMFERENCE; BEHAVIOR THERAPY; COMPLICATION; COST BENEFIT ANALYSIS; MIDDLE AGED; PSYCHOLOGY; PSYCHOSIS; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; BEHAVIOR THERAPY; BIPOLAR DISORDER; CARDIOVASCULAR DISEASES; CHOLESTEROL; COST-BENEFIT ANALYSIS; ENGLAND; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 85041125281     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(18)30490-5     Document Type: Erratum

References (26)

1. Osborn, DJ, Levy, G, Nazareth, I, Petersen, I, Islam, A, King, MB, Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's general practice research database. Arch Gen Psychiatry 64 (2007), 242–249.
2. Hayes, JF, Marston, L, Walters, K, King, MB, Osborn, DPJ, Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014. Br J Psychiatry 211 (2017), 175–181.
3. Olfson, M, Gerhard, T, Huang, C, et al. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 72 (2015), 1172–1181.
4. McGinty, R, Baller, J, Azrin, S, Juliano-Bult, D, Daumit, G, Interventions to address medical conditions and health-risk behaviors among persons with serious mental illness: a comprehensive review. Schizophr Bull 42 (2016), 96–124.
5. Gierisch, JM, Nieuwsma, JA, Bradford, DW, et al. Interventions to improve cardiovascular risk factors in people with serious mental illness. 2013, Agency for Healthcare Research and Quality, Rockville, MD.
6. Blackburn, R, Osborn, D, Walters, K, Falcaro, M, Nazareth, I, Petersen, I, Statin prescribing for people with severe mental illnesses: a staggered cohort study of ‘real-world’ impacts. BMJ Open, 7, 2017, e013154.
7. Zomer, E, Osborn, D, Nazareth, I, et al. Effectiveness and cost-effectiveness of a cardiovascular risk prediction algorithm for people with severe mental illness (PRIMROSE). BMJ Open, 7, 2017, e018181.
8. Burton, A, Osborn, D, Atkins, L, et al. Lowering cardiovascular disease risk for people with severe mental illnesses in primary care: a focus group study. PLoS One, 10, 2015, e0136603.
9. Michie, S, van Stralen, MM, West, R, The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci, 6, 2011, 42.
10. Osborn, D, Burton, A, Walters, K, et al. Evaluating the clinical and cost effectiveness of a behaviour change intervention for lowering cardiovascular disease risk for people with severe mental illnesses in primary care (PRIMROSE study): study protocol for a cluster randomised controlled trial. Trials, 17, 2016, 80.
11. British Heart Foundation. Keep your heart healthy. https://www.bhf.org.uk/publications/heart-conditions/keep-your-heart-healthy (accessed Oct 1, 2015).
12. Osborn, DP, Hardoon, S, Omar, RZ, et al. Cardiovascular risk prediction models for people with severe mental illness: results from the prediction and management of cardiovascular risk in people with severe mental illnesses (Primrose) research program. JAMA Psychiatry 72 (2015), 143–151.
13. Faulkner, G, Cohn, T, Remington, G, Validation of a physical activity assessment tool for individuals with schizophrenia. Schizophr Res 82 (2006), 225–231.
14. Roe, L, Strong, C, Whiteside, C, Neil, A, Mant, D, Dietary intervention in primary care: validity of the DINE method for diet assessment. Fam Pract 11 (1994), 375–381.
15. Saunders, JB, Aasland, OG, Babor, TF, de la Fuente, JR, Grant, M, Development of the Alcohol Use Disorders Screening Test (AUDIT). WHO collaborative project on early detection of persons with harmful alcohol consumption. Addiction 88 (1993), 791–804.
16. Tennant, R, Hiller, L, Fishwick, R, et al. The Warwick-Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation. Health Qual Life Outcomes, 5, 2007, 63.
17. Oppe, M, Devlin, N, van Hout, B, Krabbe, P, de Charro, F, A program of methodological research to arrive at the new international EQ-5D-5 L valuation protocol. Value Health 17 (2014), 445–453.
18. Morisky, DE, Green, LW, Levine, DM, Concurrent and predictive validity of a self reported measure of medication adherence. Med Care 24 (1986), 67–74.
19. Attkisson, CC, Zwick, R, The client satisfaction questionnaire: psychometric properties and correlations with service utilization and psychotherapy outcome. Eval Program Plann 5 (1982), 233–237.
20. Eldridge, SM, Ashby, D, Feder, GS, Rudnicka, AR, Ukoumunne, OC, Lessons for cluster randomized trials in the twenty-first century: a systematic review of trials in primary care. Clin Trials 1 (2004), 80–90.
21. Ruggeri, M, Leese, M, Thornicroft, G, Bisoffi, G, Tansella, M, Definition and prevalence of severe and persistent mental illness. Br J Psychiatry 177 (2000), 149–155.
22. Banham, L, Gilbody, S, Smoking cessation in severe mental illness: what works?. Addiction 105 (2010), 1176–1189.
23. Cooper, SJ, Reynolds, GP, Barnes, T, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol 30 (2016), 717–748.
24. Osborn, DPJ, Baio, G, Walters, K, et al. Inequalities in the provision of cardiovascular screening to people with severe mental illnesses in primary care: cohort study in the United Kingdom THIN Primary Care Database 2000–2007. Schizophr Res 129 (2011), 104–110.
25. Druss, BG, von Esenwein, SA, Glick, GE, et al. Randomized trial of an integrated behavioral health home: the Health Outcomes Management and Evaluation (HOME) study. Am J Psychiatry 174 (2017), 246–325.
26. Chwastiak, L, Fortney, J, Learning to integrate cardiometabolic care in serious mental illness. Am J Psychiatry 174 (2017), 199–201.